Cassava will stop developing simufilam for Alzheimer’s this year after a Phase 3 trial failed to improve cognition and daily ...

Cassava Sciences has given up on simufilam in Alzheimer’s disease. | Cassava Sciences has given up on simufilam in ...

While investigations into the drug are stopping in Alzheimer’s disease, the therapy is now being evaluated in TSC-related ...

Cassava Sciences has officially ended development of simufilam in Alzheimer’s disease, marking the end of a tumultuous era ...

(Reuters) -Cassava Sciences said on Tuesday its Alzheimer's drug simufilam, which has been at the center of regulatory ...

The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by doctors and ...

The company ended 2024 with just under $127 million in cash reserves, and nothing in its pipeline beyond the Alzheimer's ...

US biotech Cassava Sciences (Nasdaq: SAVA) will shut down development of its lead Alzheimer’s disease candidate, simufilam, after the treatment failed a second late-stage trial. Top-line results from ...

We are disappointed that the results of REFOCUS-ALZ and RETHINK-ALZ showed no treatment benefit for patients with mild-to-moderate Alzheimer’s ...

Cassava Sciences faces a significant setback after announcing its drug Simufilam failed to achieve meaningful results in the ...

Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with ...

Cassava Sciences has officially stopped the development of its investigational drug simufilam in Alzheimer’s disease after it failed to show benefit in a second Phase III trial. The company is ...